These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

360 related articles for article (PubMed ID: 26365597)

  • 1. Improvement of tuberous sclerosis complex (TSC) skin tumors during long-term treatment with oral sirolimus.
    Nathan N; Wang JA; Li S; Cowen EW; Haughey M; Moss J; Darling TN
    J Am Acad Dermatol; 2015 Nov; 73(5):802-8. PubMed ID: 26365597
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Efficacy and Safety of Topical Sirolimus Therapy for Facial Angiofibromas in the Tuberous Sclerosis Complex : A Randomized Clinical Trial.
    Wataya-Kaneda M; Nakamura A; Tanaka M; Hayashi M; Matsumoto S; Yamamoto K; Katayama I
    JAMA Dermatol; 2017 Jan; 153(1):39-48. PubMed ID: 27837201
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Analysis of current data on the use of topical rapamycin in the treatment of facial angiofibromas in tuberous sclerosis complex.
    Balestri R; Neri I; Patrizi A; Angileri L; Ricci L; Magnano M
    J Eur Acad Dermatol Venereol; 2015 Jan; 29(1):14-20. PubMed ID: 25174683
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Clinical and Histologic Analysis of the Efficacy of Topical Rapamycin Therapy Against Hypomelanotic Macules in Tuberous Sclerosis Complex.
    Wataya-Kaneda M; Tanaka M; Yang L; Yang F; Tsuruta D; Nakamura A; Matsumoto S; Hamasaki T; Tanemura A; Katayama I
    JAMA Dermatol; 2015 Jul; 151(7):722-30. PubMed ID: 25692384
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Long-term treatment of cutaneous manifestations of tuberous sclerosis complex with topical 1% sirolimus cream: A prospective study of 25 patients.
    Malissen N; Vergely L; Simon M; Roubertie A; Malinge MC; Bessis D
    J Am Acad Dermatol; 2017 Sep; 77(3):464-472.e3. PubMed ID: 28502378
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Efficacy and Safety of Topical Rapamycin in Patients With Facial Angiofibromas Secondary to Tuberous Sclerosis Complex: The TREATMENT Randomized Clinical Trial.
    Koenig MK; Bell CS; Hebert AA; Roberson J; Samuels JA; Slopis JM; Tate P; Northrup H;
    JAMA Dermatol; 2018 Jul; 154(7):773-780. PubMed ID: 29800048
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Sirolimus Gel Treatment vs Placebo for Facial Angiofibromas in Patients With Tuberous Sclerosis Complex: A Randomized Clinical Trial.
    Wataya-Kaneda M; Ohno Y; Fujita Y; Yokozeki H; Niizeki H; Ogai M; Fukai K; Nagai H; Yoshida Y; Hamada I; Hio T; Shimizu K; Murota H
    JAMA Dermatol; 2018 Jul; 154(7):781-788. PubMed ID: 29800026
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Clinical Characteristics of Connective Tissue Nevi in Tuberous Sclerosis Complex With Special Emphasis on Shagreen Patches.
    Bongiorno MA; Nathan N; Oyerinde O; Wang JA; Lee CR; Brown GT; Moss J; Darling TN
    JAMA Dermatol; 2017 Jul; 153(7):660-665. PubMed ID: 28445558
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Successful treatment of subungual fibromas of tuberous sclerosis with topical rapamycin.
    Muzic JG; Kindle SA; Tollefson MM
    JAMA Dermatol; 2014 Sep; 150(9):1024-5. PubMed ID: 24919623
    [No Abstract]   [Full Text] [Related]  

  • 10. Efficacy and Safety of Mammalian Target of Rapamycin Inhibitor Use-Long-term Follow-up of First Tuberous Sclerosis Complex Patient Treated De Novo With Sirolimus After Kidney Transplantation: A Case Report.
    Tarasewicz A; Dębska-Ślizień A; Rutkowska B; Szurowska E; Matuszewski M
    Transplant Proc; 2018; 50(6):1904-1909. PubMed ID: 30056926
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Topical sirolimus for the treatment of angiofibromas in tuberous sclerosis.
    Cinar SL; Kartal D; Bayram AK; Canpolat M; Borlu M; Ferahbas A; Per H
    Indian J Dermatol Venereol Leprol; 2017; 83(1):27-32. PubMed ID: 27643542
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Topical use of mammalian target of rapamycin inhibitors in dermatology: A systematic review with meta-analysis.
    Leducq S; Giraudeau B; Tavernier E; Maruani A
    J Am Acad Dermatol; 2019 Mar; 80(3):735-742. PubMed ID: 30744877
    [TBL] [Abstract][Full Text] [Related]  

  • 13. First left-right comparative study of topical rapamycin vs. vehicle for facial angiofibromas in patients with tuberous sclerosis complex.
    Tanaka M; Wataya-Kaneda M; Nakamura A; Matsumoto S; Katayama I
    Br J Dermatol; 2013 Dec; 169(6):1314-8. PubMed ID: 23909960
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Topical rapamycin inhibits tuberous sclerosis tumor growth in a nude mouse model.
    Rauktys A; Lee N; Lee L; Dabora SL
    BMC Dermatol; 2008 Jan; 8():1. PubMed ID: 18226258
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Comparison of three rapamycin dosing schedules in A/J Tsc2+/- mice and improved survival with angiogenesis inhibitor or asparaginase treatment in mice with subcutaneous tuberous sclerosis related tumors.
    Woodrum C; Nobil A; Dabora SL
    J Transl Med; 2010 Feb; 8():14. PubMed ID: 20146790
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Use of mTOR inhibitors (rapalogs) for the treatment of skin changes in tuberous sclerosis complex.
    Farges D; Sigg N; Ville D; Martin L
    Arch Pediatr; 2022 Dec; 29(5S):5S20-5S24. PubMed ID: 36585067
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Comparative Effects of Topical 0.2% Sirolimus for Angiofibromas in Adults and Pediatric Patients with Tuberous Sclerosis Complex.
    Lee YI; Lee JH; Kim DY; Chung KY; Shin JU
    Dermatology; 2018; 234(1-2):13-22. PubMed ID: 29925060
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Tuberous Sclerosis Complex in 29 Children: Clinical and Genetic Analysis and Facial Angiofibroma Responses to Topical Sirolimus.
    Wang S; Liu Y; Wei J; Zhang J; Wang Z; Xu Z
    Pediatr Dermatol; 2017 Sep; 34(5):572-577. PubMed ID: 28771801
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A novel topical rapamycin cream for the treatment of facial angiofibromas in tuberous sclerosis complex.
    Wheless JW; Almoazen H
    J Child Neurol; 2013 Jul; 28(7):933-6. PubMed ID: 23680945
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A Review of Topical Sirolimus for the Treatment of Facial Angiofibromas in Tuberous Sclerosis Complex.
    Dao DD; Pixley JN; Akkurt ZM; Feldman SR
    Ann Pharmacother; 2024 Apr; 58(4):428-433. PubMed ID: 37386842
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 18.